374795-76-3

Basic information

• Product Name: tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
• Synonyms: tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate;tert-Butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)
• CAS NO: 374795-76-3
• Molecular Formula: C11H17N3O2
• Molecular Weight: 223.27158
• EINECS: -0
• Mol File: 374795-76-3.mol

Chemical Properties

• Boiling Point: 396.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.62±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate(374795-76-3)
• EPA Substance Registry System: tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate(374795-76-3)

Safety Data

• Hazardous Substances Data: 374795-76-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate is used as an intermediate in the synthesis of aryl-amido-cyclohexane derivatives. These derivatives have potential applications in the development of new drugs due to their diverse chemical properties and potential biological activities.
Used in the Development of NK-1 Receptor Antagonists:
tert-Butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate is also used in the development of NK-1 receptor antagonists. NK-1 receptor antagonists are a class of drugs that block the action of substance P at the NK-1 receptor, which is involved in various physiological processes, including pain transmission, inflammation, and emesis. By acting as an intermediate in the synthesis of these antagonists, tert-butyl 5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate plays a crucial role in the development of new treatments for conditions such as migraine, postoperative pain, and nausea and vomiting associated with chemotherapy.

Relevant articles and documents

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.